CORONA Remedies Limited has achieved a key milestone in its global expansion journey with the successful accreditation of the EAEU–GMP (Eurasian Economic Union – Good Manufacturing Practices) certification.

The certification enables CORONA Remedies to enter five EAEU member countries—Russia, Kyrgyzstan, Armenia, Belarus, and Kazakhstan—under a B2B business model, providing access to a pharmaceutical market estimated at USD 25 billion. The development aligns with the company’s long-term strategy of building sustainable international partnerships.

EAEU–GMP accreditation further strengthens CORONA’s presence across its four core therapeutic areas—Women’s Health, Cardio-Diabetes, Pain Management, and Urology.

Commenting on the achievement, Nirav K. Mehta, CEO & Managing Director, said the certification opens new avenues for CORONA to contribute to healthcare systems across the Eurasian region and reflects the company’s belief that quality healthcare should transcend geographical boundaries. He added that the milestone marks an important step toward becoming a trusted international partner in pharmaceutical innovation, with a continued focus on quality-driven and scalable solutions.

CORONA Remedies said it is among the few pharmaceutical manufacturers in Gujarat to receive the prestigious certification, underscoring its operational excellence, robust quality systems, and compliance with global regulatory standards.

Guided by its philosophy of “One World, One Quality,” the company said it will continue to deliver safe, effective, and trusted medicines while strengthening its footprint in India and overseas.